Most people with type 2 diabetes are either overweight or obese, and many are severely so. Although the potential benefits of weight loss for people with type 2 diabetes are profound, weight loss is seldom a major treatment goal, and many diabetes-trained healthcare professionals remain ill-equipped to help patients tackle their obesity. This article examines the current evidence for offering antiobesity drugs or bariatric surgery in the routine management of type 2 diabetes and suggests when and in whom these treatment modalities should be considered.
Key words
- Obesity
- Bariatric surgery
- Antiobesity agents
**********
Most Popular
Question For The Ages: What Is Time Management?
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
Obesity is intimately linked with type 2 diabetes (Colditz et al, 1995; Chan et al, 1994), and the overwhelming majority of people with type 2 diabetes are overweight or obese. In a recent survey of people with type 2 diabetes attending a secondary care diabetes clinic in Liverpool, as few as 14% had a healthy BMI, while 52% had a BMI >30kg/[m.sup.2], 24% had a BMI >35g/[m.sup.2], and 8.1% a BMI >40kg/[m.sup. paroxetine. 2] (Daousi et al, 2006). In the same study it was found that the presence of obesity was associated with poorer glycaemic control, increased needs for other drug therapy, and further exacerbated the risks of hypertension, dyslipidaemia and macrovascular disease. These prevalence figures far exceed the prevalence of obesity in the background population predicted from the Health Survey for England (The Information Centre, 2006), and show also that severe obesity (BMI >40kg/[m.sup.2]; grade 3 or morbid obesity) is now commonplace among people with type 2 diabetes, particularly in women–a striking and poorly understood finding. Despite the many advances in diabetes care over the last three decades, life expectancy for middle-aged people with diabetes remains lower than the population average by, on average, 8 years (Roper et al, 2001). Clearly, more effective control of type 2 diabetes has become a national imperative and there is now increasing interest in weight loss as a means to achieve this.
Short-term experimental studies in people who are overweight with established type 2 diabetes clearly showed that weight loss restores blood glucose and insulin sensitivity to near-normal (Henry et al, 1986). A variety of other studies of intensive dietary interventions–alone or in combination with exercise or behavioural therapy–also demonstrate improved glycaemic control in obese individuals with type 2 diabetes (Pinkney and Wilding, 2004). Furthermore, epidemiological data suggest that weight loss reduces mortality in people with diabetes by around one quarter (Williamson et al, 2000). It would follow that the ideal treatment to prevent and control diabetes would emphasise caloric restriction, physical activity and weight loss. So, what do antiobesity drugs and bariatric surgery have to offer?
Antiobesity drugs
Currently, there are three antiobesity drugs licensed in Europe for long term treatment–orlistat (Xenical; Roche, Welwyn Garden City), sibutramine (Reductil; Abbot, Maidenhead) and rimonabant (Acomplia; Sanofi-Aventis, Guildford).
Orlistat is an inhibitor of intestinal and pancreatic lipases and can result in a 30% reduction in the absorption of dietary fat.
Sibutramine is a drug that acts on the brain to inhibit re-uptake of the neurotransmitters serotonin and norepinephrine and is believed to exert its effects by increasing satiety and enhancing energy expenditure after meals.
Rimonabant is a cannabinoid receptor antagonist that reduces body weight mainly by reducing appetite, through an action on the reward centres in the brain. Rimonabant reduces appetite by suppressing the pleasurable aspect of eating, and also appears to have a variety of peripheral actions to reduce body fat and favourably influence the metabolic syndrome (Padwal and Majumdar, 2007). Rimonabant was licensed in 2006 for use as an adjunct to diet and exercise for the treatment of obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia.
NICE has previously summarised much of the evidence on the use of orlistat and sibutramine (NICE, 2001a; 2001b) and updated its review in 2006 (NICE, 2006), although these documents relate principally to people without diabetes and do not specifically address the potential role of antiobesity drugs in diabetes management. Although rimonabant has not yet been considered, we recommend it is used in a similar way to orlistat and sibutramine. The NICE guidance endorses the selective use of orlistat and sibutramine in highly motivated individuals treated in the context of an expert, structured, multidisciplinary management programme. What defines such a programme has been set out in the Royal College of Physicians 2003 report (Table 1).
When to consider an antiobesity drug for a patient with type 2 diabetes
For all people newly diagnosed with type 2 diabetes it is appropriate to ask the question: ‘would this particular individual benefit from a management programme that prioritises weight reduction and is there a realistic chance that the treatment could work?’ If that question can be answered affirmatively–which it often can be–then antiobesity drugs are one set of tools to be considered.